Result for
Topic: Vaccines and Immunity
February 10, 2021
Patterns of COVID-19 Pandemic Dynamics Following Deployment of a Broad National Immunization Program
[Pre-print, not peer-reviewed] An analysis of data from the Israeli Ministry of Health showed that by February 6, 2021, 45% of the Israeli population had received a first dose of the Pfizer/BioNTech vaccine or had recovered from COVID-19 and 30% had received both doses or recovered form COVID-19. The proportions among those age 60 or…
Understanding Drivers of COVID-19 Vaccine Hesitancy Among Black Community
Findings from focus groups conducted in July and August, 2020 among Black barbershop and salon owners (n=24) living in areas of higher COVID-19 prevalence showed that COVID-19 vaccine hesitancy was high due to mistrust in the medical establishment, concerns regarding the speed of vaccine development, a perception of lack of data on side effects, fear…
Coronavirus Disease 2019 Vaccine Hesitancy among Children’s Hospital Staff: A Single-Center Survey
Among children’s hospital clinical and non-clinical staff (n=4,448) who responded to an electronic survey on the first day of the hospital’s administration of the Pfizer/BioNTech COVID-19 vaccine, the majority of respondents (60%) reported they would definitely receive the vaccine, and 9% had already received the vaccine. Vaccine hesitancy was reported among 19% of respondents, and…
COVID-19 Vaccine Acceptability among U.S. Firefighters and Emergency Medical Services Workers
Findings from a cross-sectional survey conducted in October 2020 among firefighters and EMTs (n=3,169) showed that 48% of respondents expressed high acceptability of a future COVID-19 vaccine, while 24% reported that they were unsure and 28% reported low acceptability. Groups with greater odds of reporting low acceptability (relative to the high acceptability group) included individuals…
Neutralization of SARS-CoV-2 Spike 69/70 Deletion, E484K and N501Y Variants by BNT162b2 Vaccine-Elicited Sera
Human sera from 20 participants who received both doses of the Pfizer/BioNTech vaccine showed equivalent neutralization titers (with differences of four-fold or less) between wild type and variants strains of SARS-CoV-2 viruses that were engineered to contain spike proteins from recently emerged variants. The combinations of mutations included N501Y (present in variants emerging from the…
February 9, 2021
COVID-19 Vaccination Intent, Perceptions, and Reasons for Not Vaccinating Among Groups Prioritized for Early Vaccination — United States, September and December 2020
Among US adults in priority groups, intent to receive COVID-19 vaccination increased from 39% in September 2020 to 49% in December 2020, according to two separate nationally representative cross-sectional surveys conducted by the CDC (n=3,541 in September and n=2,033 in December). While vaccination non-intent also decreased from 38% to 32%, younger adults, women, non-Hispanic Black…
Decreased SARS-CoV-2 Viral Load Following Vaccination
[Pre-print, not peer-reviewed] SARS-CoV-2 PCR positive samples collected from persons 12-28 days after receiving the first dose of the Pfizer vaccine had lower viral load concentrations compared to positive samples from non-vaccinated demographically matched persons (based on cycle threshold (Ct) counts to detect genes associated with SARS-CoV-2). The increase in Ct count corresponded to a…
February 8, 2021
Infection and MRNA-1273 Vaccine Antibodies Neutralize SARS-CoV-2 UK Variant
[Pre-print, not peer-reviewed] A study using a live virus neutralization assay to compare potency of neutralization between people who had been infected with SARS-CoV-2 or had received the Moderna COVID-19 vaccine against a panel of SARS-CoV-2 variants showed that antibodies in sera from both groups were effective at neutralizing the B.1.1.7 variant. Serum neutralization titers…
Antibody Responses Boosted in Seropositive Healthcare Workers after Single Dose of SARS-CoV-2 MRNA Vaccine
[Pre-print, not peer-reviewed] Among healthcare workers who received a single dose of the Pfizer/BioNTech vaccine, those who had SARS-CoV-2 infection 30-60 days prior to vaccination (n = 36) had significantly higher antibody levels at 3 weeks post-vaccination than individuals with no prior infection (n = 152). After the first vaccine dose, both previously infected and…
Efficacy or Delivery? An Online Discrete Choice Experiment to Explore Preferences for COVID-19 Vaccines in the UK
An online discrete choice experiment study enrolling participants in the UK (n = 1,501) to assess the relative impact of vaccine properties, delivery and media coverage on vaccine uptake showed that efficacy was the factor the most influential in uptake (OR = 2.8 for 90% efficacy versus 70% efficacy), and the positive effect of high…
Previous page Next page